Live price temporarily unavailable.
Spruce Biosciences (SPRB) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | $0 | $10.1M | $4.91M | $0 |
| Growth (year over year) | — | — | — | — | — | −51.3% | −100.0% |
| Operating income | −$13.1M | −$29.4M | −$42.1M | −$47.3M | −$52.0M | −$56.2M | −$36.5M |
| Operating margin | — | — | — | — | −515.3% | −1143.4% | — |
| Net income | −$13.1M | −$29.5M | −$42.3M | −$46.2M | −$47.9M | −$53.0M | −$39.0M |
| Net margin | — | — | — | — | −475.0% | −1079.9% | — |
| EPS (diluted) | −$17.12 | −$4.93 | −$1.81 | −$1.96 | −$1.24 | −$96.40 | −$50.83 |
| Balance sheet | |||||||
| Cash and equivalents | $3.92M | $157.2M | $42.7M | $24.5M | $96.3M | $38.8M | $48.9M |
| Total assets | $4.69M | $162.9M | $126.5M | $85.6M | $103.9M | $45.2M | $53.0M |
| Total liabilities | $7.52M | $13.5M | $15.1M | $17.2M | $27.4M | $16.4M | $10.5M |
| Long-term debt | $3.19M | $1.92M | $4.88M | $3.29M | $1.72M | $124.0K | $0 |
| Shareholders' equity | −$30.6M | $149.4M | $111.4M | $68.5M | $76.5M | $28.8M | $42.5M |
| Cash flow | |||||||
| Operating cash flow | −$12.6M | −$27.5M | −$35.9M | −$41.7M | −$33.3M | −$56.0M | −$33.3M |
| Capital expenditure | $4.00K | $74.0K | $93.0K | $8.00K | $7.00K | $0 | — |
| Free cash flow | −$12.6M | −$27.6M | −$36.0M | −$41.7M | −$33.3M | −$56.0M | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $602.0K | $697.0K | $0 | $0 | $0 | — | — | — |
| Growth (year over year) | −80.4% | −75.9% | −100.0% | −100.0% | −100.0% | — | — | — |
| Operating income | −$9.41M | −$24.1M | −$14.5M | −$2.69M | −$8.23M | — | −$12.0M | −$16.5M |
| Operating margin | −1562.8% | −3453.9% | — | — | — | — | — | — |
| Net income | −$8.67M | −$23.6M | −$14.0M | −$2.07M | −$8.21M | — | −$12.3M | −$16.2M |
| Net margin | −1440.4% | −3380.1% | — | — | — | — | — | — |
| EPS (diluted) | −$15.75 | −$63.64 | −$23.95 | −$3.50 | −$14.58 | — | −$8.94 | −$6.68 |
| Balance sheet | ||||||||
| Cash and equivalents | $60.1M | $38.8M | $25.6M | $16.4M | $10.7M | $48.9M | $54.1M | $96.3M |
| Total assets | $65.1M | $45.2M | $31.6M | $21.8M | $15.3M | $53.0M | $56.2M | $102.9M |
| Total liabilities | $13.5M | $16.4M | $16.3M | $8.64M | $9.93M | $10.5M | $21.5M | $19.1M |
| Long-term debt | $524.0K | $124.0K | $0 | $0 | $0 | $0 | $5.46M | $4.59M |
| Shareholders' equity | $51.6M | $28.8M | $15.3M | $13.2M | $5.39M | $42.5M | $34.6M | $83.7M |
| Cash flow | ||||||||
| Operating cash flow | −$9.22M | −$20.7M | −$12.7M | −$8.83M | −$5.32M | — | −$8.73M | −$22.1M |
| Capital expenditure | — | $0 | $0 | $0 | — | — | $10.0K | $135.0K |
| Free cash flow | — | −$20.7M | −$12.7M | −$8.83M | — | — | −$8.74M | −$22.3M |
From Spruce Biosciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Spruce Biosciences in our feed yet.